⭐️ECLYPse II期：BRAF V600E mCRC患者在EC治疗期间疾病进展后，进展后继续使用Encorafenib + cetuximab并联合FOLFIRI
#ESMO26
✅ 6个月PFS率：66.7%（12/18；达到主要终点阈值）
👉 中位PFS（mPFS）：7.1个月（6.2–NA）
👉 中位OS（mOS）：未达到（NR）
👉 ORR 15% | DCR 80%
#OncTwitter #Oncology #ESMO @myESMO #MedTwitter
3 浏览 · 0 赞 · 1 转发 · 0 回复
STARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
https://esmocongress.esmo.orgEncorafenib plus cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E metastatic colorectal cancer (mCRC) patients (pts) progressing on EC: Results from the ECLYPse phase II trial
https://esmocongress.esmo.org- **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
https://esmocongress.esmo.org- **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
https://esmocongress.esmo.org来源：OncUpdates · x.com